[Randomized trial comparing UFT and FT-207 in the treatment of advanced hepatocellular carcinoma (first report: well controlled study on the patients for whom transcatheter arterial embolization could not be applied) Osaka Research Society for Liver, Gallbladder and Pancreas].

Abstract

In a randomized trial, Tegafur (FT-207) or Tegafur-Uracil (UFT) was administrated to 76 patients with advanced hepatocellular carcinoma for whom transcatheter arterial embolization could not be applied. Efficacy on the reduction of tumor size, subjective symptoms and clinical laboratory findings were comparable in both groups. However, survival rate in the UFT group was significantly higher than in the FT-207 group in only 3 limited subgroups of patients: with nodular type tumor, with main nodule of less than 5 cm in maximum diameter, and without prior chemotherapy. Incidence of adverse effects were higher in UFT group than FT-207 group, but not significantly.

• Authors: J Kojima, T Kamata, T Monna
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 17 Issue 5 Pg. 1005-13 (May 1990) ISSN: 0385-0684 [Print] Japan
• PMID: 2159264 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Tegafur
• Uracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, mortality)
• Embolization, Therapeutic
• Female
• Humans
• Liver Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Multicenter Studies as Topic
• Prognosis
• Randomized Controlled Trials as Topic
• Survival Rate
• Tegafur (administration & dosage)
• Uracil (administration & dosage)